Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
about
Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer.A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
P2860
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@en
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@nl
type
label
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@en
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@nl
prefLabel
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@en
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@nl
P2093
P1433
P1476
Phase II study of bevacizumab, ...... metastatic colorectal cancer.
@en
P2093
Alberto Muñoz
Carlos García-Girón
Esther Falcó
Fernando Rivera
Iñaki Alvarez Bustos
Luis Cirera
Rosario Dueñas
Vicente Alonso
P304
P356
10.3727/096504014X13887748696743
P577
2013-01-01T00:00:00Z